Encision Inc.

OTC: ECIA    
Share price (5/13/24): $0.50    
Market cap (5/13/24): $5.938 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 16 pages Material contract
12/34/56
EX-10.9
from 10-Q 4 pages Material contract
12/34/56
EX-10.1
from 10-Q 27 pages Certain Identified Information Has Been Omitted From This Document Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed, and Has Been Marked With “[***]” to Indicate Where Omissions Have Been Made Supply Agreement
12/34/56
EX-10.1
from 10-Q 6 pages Ppp Promissory Note Dated February 8, 2021.
12/34/56
EX-10.1
from 10-Q 1 page Material contract
12/34/56
EX-10.1
from 8-K 4 pages Material contract
12/34/56
EX-10.1
from 10-Q 1 page Material contract
12/34/56
EX-10.1
from 8-K 8 pages Encision Inc. Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 8 pages Encision Inc. Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 15 pages Material contract
12/34/56
EX-10.1
from 10-Q 5 pages Fifth Amendment to Lease
12/34/56
EX-10.1
from 10-Q 14 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 14 pages Employment Agreement
12/34/56
EX-10.3
from 8-K 14 pages Employment Agreement
12/34/56
EX-10.2
from 8-K 18 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 30 pages Encision Inc. Securities Purchase Agreement Encision Inc. Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 2 pages 1. as a Result of Your Ability to Raise Additional Capital for the Company, the Company Holds a Stronger Balance Sheet and Will Enable It to Conduct Sales, Marketing and Engineering Initiatives for the Future Prospect of the Company. However, These Initiatives Are an Additional Expense and May Cause the Company to Experience Two Consecutive Quarters of Net Losses
12/34/56
EX-10.1
from 8-K 14 pages Employment Agreement
12/34/56
EX-10.4
from 10-K 19 pages [*] = Certain Confidential Information Contained in This Document, Marked With Brackets, Has Been Omitted and Filed Separately With the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment Made Pursuant to Rule 24b-2 Under the Securities Exchange Act of 1934, as Amended. January 19, 2011 Jack Serino President & CEO Encision Inc. 6797 Winchester Circle Boulder, Co 80301 This Letter Constitutes a Development, License, and Non-Commercial Supply Agreement (“Agreement”) Between Encision and Boston Scientific, Effective as of the Date Both Parties Have Executed the Agreement (“Effective Date”)
12/34/56
EX-10.1
from 8-K 3 pages Agreement
12/34/56